FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018629339> ?p ?o ?g. }

• W2018629339 endingPage "1214" @default.
• W2018629339 startingPage "1208" @default.
• W2018629339 abstract "Background Autophagy is a conserved response to stress that facilitates cell survival in some contexts and promotes cell death in others. We sought to characterize autophagy in papillary thyroid cancer (PTC), and to determine the effects of autophagy inhibition on chemosensitivity and radiosensitivity. Methods The human thyroid papillary carcinoma cell lines TPC-1 and 8505-C were treated with doxorubicin or radiation in the presence or absence of the autophagy-specific inhibitor 3-methyladenine (3-MA). Results Although light chain 3 (LC3)-II protein levels were undetectable in normal thyroid and PTC specimens at baseline, doxorubicin exposure induced LC3-II expression and the formation of autophagosomes. Both PTC cell lines expressed low levels of LC3-II under standard conditions. Treatment of these cells with doxorubicin strongly induced LC3-II expression and the formation of autophagosomes; however, doxorubicin–mediated induction of LC3-II was abrogated by 3-MA. Moreover, 3-MA significantly increased the doxorubicin IC50 in both PTC cell lines. Radiation exposure also induced LC3-II expression. Treatment with 3-MA abrogated the radiation–induced increase in LC3-II in both cell lines and reduced radiosensitivity by 49% and 31% in 8505-C and TPC-1 cells, respectively. Conclusion Autophagy inhibition promotes PTC resistance to doxorubicin and radiation. Therefore, autophagy activation may be a useful adjunct treatment for patients with PTC that is refractory to conventional therapy. Autophagy is a conserved response to stress that facilitates cell survival in some contexts and promotes cell death in others. We sought to characterize autophagy in papillary thyroid cancer (PTC), and to determine the effects of autophagy inhibition on chemosensitivity and radiosensitivity. The human thyroid papillary carcinoma cell lines TPC-1 and 8505-C were treated with doxorubicin or radiation in the presence or absence of the autophagy-specific inhibitor 3-methyladenine (3-MA). Although light chain 3 (LC3)-II protein levels were undetectable in normal thyroid and PTC specimens at baseline, doxorubicin exposure induced LC3-II expression and the formation of autophagosomes. Both PTC cell lines expressed low levels of LC3-II under standard conditions. Treatment of these cells with doxorubicin strongly induced LC3-II expression and the formation of autophagosomes; however, doxorubicin–mediated induction of LC3-II was abrogated by 3-MA. Moreover, 3-MA significantly increased the doxorubicin IC50 in both PTC cell lines. Radiation exposure also induced LC3-II expression. Treatment with 3-MA abrogated the radiation–induced increase in LC3-II in both cell lines and reduced radiosensitivity by 49% and 31% in 8505-C and TPC-1 cells, respectively. Autophagy inhibition promotes PTC resistance to doxorubicin and radiation. Therefore, autophagy activation may be a useful adjunct treatment for patients with PTC that is refractory to conventional therapy." @default.
• W2018629339 created "2016-06-24" @default.
• W2018629339 creator A5003360187 @default.
• W2018629339 creator A5006476950 @default.
• W2018629339 creator A5018703548 @default.
• W2018629339 creator A5032807087 @default.
• W2018629339 creator A5044265138 @default.
• W2018629339 creator A5047151049 @default.
• W2018629339 creator A5061257236 @default.
• W2018629339 creator A5072328168 @default.
• W2018629339 date "2009-12-01" @default.
• W2018629339 modified "2023-09-27" @default.
• W2018629339 title "Autophagy: A new target for advanced papillary thyroid cancer therapy" @default.
• W2018629339 cites W1963521777 @default.
• W2018629339 cites W1966895889 @default.
• W2018629339 cites W1968747252 @default.
• W2018629339 cites W1972336737 @default.
• W2018629339 cites W1977767269 @default.
• W2018629339 cites W1980102456 @default.
• W2018629339 cites W1990196512 @default.
• W2018629339 cites W1997714593 @default.
• W2018629339 cites W1999093552 @default.
• W2018629339 cites W2003059814 @default.
• W2018629339 cites W2014319455 @default.
• W2018629339 cites W2028080080 @default.
• W2018629339 cites W2032739603 @default.
• W2018629339 cites W2055249187 @default.
• W2018629339 cites W2070860179 @default.
• W2018629339 cites W2074489279 @default.
• W2018629339 cites W2079282879 @default.
• W2018629339 cites W2087920955 @default.
• W2018629339 cites W2096853390 @default.
• W2018629339 cites W2097714683 @default.
• W2018629339 cites W2103782088 @default.
• W2018629339 cites W2108086395 @default.
• W2018629339 cites W2113351838 @default.
• W2018629339 cites W2136907822 @default.
• W2018629339 cites W2141884409 @default.
• W2018629339 cites W2143815536 @default.
• W2018629339 cites W2150027419 @default.
• W2018629339 cites W2156320420 @default.
• W2018629339 cites W2164337950 @default.
• W2018629339 cites W2334639861 @default.
• W2018629339 cites W4252116727 @default.
• W2018629339 doi "https://doi.org/10.1016/j.surg.2009.09.019" @default.
• W2018629339 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19958950" @default.
• W2018629339 hasPublicationYear "2009" @default.
• W2018629339 type Work @default.
• W2018629339 sameAs 2018629339 @default.
• W2018629339 citedByCount "47" @default.
• W2018629339 countsByYear W20186293392012 @default.
• W2018629339 countsByYear W20186293392013 @default.
• W2018629339 countsByYear W20186293392014 @default.
• W2018629339 countsByYear W20186293392015 @default.
• W2018629339 countsByYear W20186293392016 @default.
• W2018629339 countsByYear W20186293392017 @default.
• W2018629339 countsByYear W20186293392018 @default.
• W2018629339 countsByYear W20186293392019 @default.
• W2018629339 countsByYear W20186293392020 @default.
• W2018629339 countsByYear W20186293392021 @default.
• W2018629339 countsByYear W20186293392022 @default.
• W2018629339 countsByYear W20186293392023 @default.
• W2018629339 crossrefType "journal-article" @default.
• W2018629339 hasAuthorship W2018629339A5003360187 @default.
• W2018629339 hasAuthorship W2018629339A5006476950 @default.
• W2018629339 hasAuthorship W2018629339A5018703548 @default.
• W2018629339 hasAuthorship W2018629339A5032807087 @default.
• W2018629339 hasAuthorship W2018629339A5044265138 @default.
• W2018629339 hasAuthorship W2018629339A5047151049 @default.
• W2018629339 hasAuthorship W2018629339A5061257236 @default.
• W2018629339 hasAuthorship W2018629339A5072328168 @default.
• W2018629339 hasConcept C126322002 @default.
• W2018629339 hasConcept C1491633281 @default.
• W2018629339 hasConcept C190283241 @default.
• W2018629339 hasConcept C203522944 @default.
• W2018629339 hasConcept C206684579 @default.
• W2018629339 hasConcept C2776694085 @default.
• W2018629339 hasConcept C2779761222 @default.
• W2018629339 hasConcept C2781303535 @default.
• W2018629339 hasConcept C2781461381 @default.
• W2018629339 hasConcept C31573885 @default.
• W2018629339 hasConcept C502942594 @default.
• W2018629339 hasConcept C509974204 @default.
• W2018629339 hasConcept C526584372 @default.
• W2018629339 hasConcept C54355233 @default.
• W2018629339 hasConcept C55493867 @default.
• W2018629339 hasConcept C71924100 @default.
• W2018629339 hasConcept C81885089 @default.
• W2018629339 hasConcept C86803240 @default.
• W2018629339 hasConceptScore W2018629339C126322002 @default.
• W2018629339 hasConceptScore W2018629339C1491633281 @default.
• W2018629339 hasConceptScore W2018629339C190283241 @default.
• W2018629339 hasConceptScore W2018629339C203522944 @default.
• W2018629339 hasConceptScore W2018629339C206684579 @default.
• W2018629339 hasConceptScore W2018629339C2776694085 @default.
• W2018629339 hasConceptScore W2018629339C2779761222 @default.
• W2018629339 hasConceptScore W2018629339C2781303535 @default.
• W2018629339 hasConceptScore W2018629339C2781461381 @default.

• next